NUVB
Nuvation Bio Inc. NYSE Listed Aug 26, 2020$4.82
Mkt Cap $1.7B
52w Low $1.57
39.7% of range
52w High $9.75
50d MA $4.67
200d MA $4.99
P/E (TTM)
-7.5x
EV/EBITDA
-15.2x
P/B
5.0x
Debt/Equity
0.0x
ROE
-66.9%
P/FCF
-17.6x
RSI (14)
—
ATR (14)
—
Beta
1.61
50d MA
$4.67
200d MA
$4.99
Avg Volume
4.4M
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
1500 Broadway · New York City, NY 10036 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | AMC | -0.03 | 0.01 | +135.5% | 4.41 | -0.9% | +9.5% | +4.3% | -4.6% | -0.4% | — | — |
| Mar 2, 2026 | AMC | -0.11 | -0.11 | +0.0% | 5.84 | -17.6% | -25.3% | +8.7% | -3.6% | +0.4% | +3.1% | — |
| Nov 3, 2025 | AMC | -0.17 | -0.16 | +5.9% | 5.17 | -0.4% | -6.6% | +1.9% | +2.0% | -5.8% | -1.9% | — |
| Aug 7, 2025 | AMC | -0.17 | -0.17 | +0.0% | 2.34 | +3.4% | -1.7% | -2.6% | +3.6% | +12.5% | +5.7% | — |
| May 7, 2025 | AMC | -0.16 | -0.16 | +0.0% | 2.04 | +8.8% | +2.9% | -0.5% | +2.9% | +1.9% | -0.9% | — |
| Mar 6, 2025 | AMC | -0.14 | -0.15 | -7.1% | 1.89 | +0.0% | +6.9% | -6.9% | +21.8% | -2.2% | -1.3% | — |
| Nov 6, 2024 | AMC | -0.13 | -0.15 | -15.4% | 2.54 | +1.6% | +3.1% | +9.9% | +4.5% | -2.7% | +0.7% | — |
| Aug 5, 2024 | AMC | -0.06 | -0.15 | -150.0% | 3.18 | +0.0% | -6.3% | -4.0% | +0.7% | -1.7% | -0.4% | — |
| May 14, 2024 | AMC | -0.08 | -0.07 | +12.5% | 3.30 | +3.3% | +0.0% | +3.3% | -2.6% | +4.8% | -2.3% | — |
| Feb 29, 2024 | AMC | -0.10 | -0.06 | +40.0% | 1.87 | -0.5% | +19.3% | -4.9% | +2.8% | +9.6% | +4.2% | — |
| Nov 2, 2023 | AMC | -0.10 | -0.09 | +10.0% | 1.28 | -1.6% | +5.5% | -2.2% | +1.5% | +2.2% | -9.5% | — |
| Aug 3, 2023 | AMC | -0.11 | -0.09 | +18.2% | 1.76 | +0.0% | +4.5% | +6.0% | +5.1% | +2.4% | -6.2% | — |
| May 4, 2023 | AMC | -0.09 | -0.10 | -11.1% | 1.62 | +0.0% | +3.1% | -3.0% | -0.6% | +0.0% | +0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16 | Wedbush | Maintains | Outperform → Outperform | — | $4.82 | $4.88 | +1.2% | -0.2% | +5.6% | +0.8% | -0.2% | +0.2% |
| Apr 2 | Wedbush | Maintains | Outperform → Outperform | — | $4.51 | $4.46 | -1.1% | -2.2% | +0.9% | +1.3% | +0.4% | +2.2% |
| Mar 27 | Wedbush | Maintains | Outperform → Outperform | — | $4.42 | $4.37 | -1.1% | -3.8% | -4.7% | +5.9% | +5.1% | -2.2% |
| Mar 3 | UBS | Maintains | Neutral → Neutral | — | $5.84 | $4.81 | -17.6% | -25.3% | +8.7% | -3.6% | +0.4% | +3.1% |
| Mar 3 | RBC Capital | Maintains | Outperform → Outperform | — | $5.84 | $4.81 | -17.6% | -25.3% | +8.7% | -3.6% | +0.4% | +3.1% |
| Feb 10 | Wedbush | Maintains | Outperform → Outperform | — | $5.64 | $5.67 | +0.5% | +1.2% | +0.2% | +1.2% | -0.3% | +1.9% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $6.01 | $6.07 | +1.0% | +2.3% | -3.9% | -5.4% | -1.6% | +2.0% |
| Jan 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.04 | $7.69 | -4.4% | -19.7% | +1.4% | -3.7% | -2.7% | -4.7% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.84 | $8.11 | +3.4% | +5.5% | +1.9% | +0.9% | +1.8% | -1.6% |
| Dec 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.03 | $7.93 | -1.2% | -1.9% | -5.2% | +12.0% | -0.7% | +2.9% |
| Nov 20 | Citizens | Maintains | Market Outperform → Market Outperform | — | $7.15 | $7.20 | +0.7% | -2.0% | -0.3% | +6.0% | +6.3% | +1.6% |
| Nov 4 | Citizens | Maintains | Market Outperform → Market Outperform | — | $5.17 | $5.15 | -0.4% | -6.6% | +1.9% | +2.0% | -5.8% | -1.9% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $5.17 | $5.15 | -0.4% | -6.6% | +1.9% | +2.0% | -5.8% | -1.9% |
| Oct 13 | Wedbush | Maintains | Outperform → Outperform | — | $3.74 | $3.82 | +2.1% | -1.6% | -3.5% | +6.2% | -3.7% | -6.1% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.17 | $3.22 | +1.6% | +1.6% | +1.6% | -1.5% | +0.6% | -7.1% |
| Sep 8 | Wedbush | Maintains | Outperform → Outperform | — | $3.90 | $3.82 | -2.1% | -10.5% | -4.0% | -0.9% | +0.9% | -6.3% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $2.34 | $2.42 | +3.4% | -1.7% | -2.6% | +3.6% | +12.5% | +5.7% |
| Jun 25 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.05 | $2.03 | -1.0% | -8.3% | +4.8% | -2.0% | +1.0% | -0.5% |
| Jun 17 | RBC Capital | Maintains | Outperform → Outperform | — | $1.86 | $1.85 | -0.5% | -8.1% | +4.7% | +10.1% | +3.0% | +1.0% |
| Jun 11 | Wedbush | Maintains | Outperform → Outperform | — | $2.53 | $2.53 | +0.0% | -13.0% | -17.7% | -4.4% | +7.5% | -8.1% |
| Jun 2 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.12 | $2.17 | +2.4% | +10.4% | +4.7% | +0.0% | +1.2% | +0.0% |
| May 16 | Wedbush | Maintains | Outperform → Outperform | — | $2.24 | $2.24 | +0.0% | +0.9% | +1.8% | -5.7% | -6.5% | +10.8% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.02 | $1.80 | -10.9% | -6.9% | +21.8% | -2.2% | -1.3% | -3.2% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.65 | $2.69 | +1.5% | +4.5% | -9.0% | -0.8% | -2.0% | -1.2% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.58 | $2.57 | -0.4% | +2.7% | +4.5% | -9.0% | -0.8% | -2.0% |
| Jan 7 | RBC Capital | Maintains | Outperform → Outperform | — | $2.84 | $2.96 | +4.2% | +14.4% | -7.4% | -7.6% | -4.0% | -3.0% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.89 | $2.95 | +2.1% | -1.7% | +14.4% | -7.4% | -7.6% | -4.0% |
| Nov 7 | RBC Capital | Maintains | Outperform → Outperform | — | $2.54 | $2.58 | +1.6% | +3.1% | +9.9% | +4.5% | -2.7% | +0.7% |
| Oct 22 | Wedbush | Maintains | Outperform → Outperform | — | $2.36 | $2.36 | +0.0% | +2.1% | -3.3% | -1.3% | -3.9% | +6.3% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.05 | $3.02 | -1.0% | +0.7% | +0.0% | -5.5% | +1.7% | -5.1% |
| Sep 11 | Wedbush | Maintains | Outperform → Outperform | — | $2.94 | $2.92 | -0.7% | +4.4% | -0.3% | -0.3% | +0.7% | +0.0% |
| Aug 6 | RBC Capital | Maintains | Outperform → Outperform | — | $3.18 | $3.18 | +0.0% | -6.3% | -4.0% | +0.7% | -1.7% | -0.4% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.45 | $3.39 | -1.7% | -1.7% | -6.2% | -5.7% | +4.3% | +4.8% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.10 | $3.12 | +0.6% | -12.3% | -4.0% | +7.3% | +3.9% | -4.8% |
| May 24 | Wedbush | Maintains | Outperform → Outperform | — | $3.08 | $3.10 | +0.6% | +0.0% | -3.9% | -1.4% | +2.4% | +3.7% |
| May 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.40 | $3.41 | +0.3% | -3.5% | -6.1% | +0.0% | -3.9% | -1.4% |
| May 15 | Wedbush | Maintains | Outperform → Outperform | — | $3.30 | $3.41 | +3.3% | +0.0% | +3.3% | -2.6% | +4.8% | -2.3% |
| Apr 17 | RBC Capital | Maintains | Outperform → Outperform | — | $2.81 | $2.93 | +4.3% | -4.3% | -4.1% | +0.8% | +3.1% | +0.0% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.97 | $4.03 | +1.5% | -8.3% | +1.4% | -6.5% | +5.2% | -4.1% |
| Mar 27 | Jefferies | Upgrade | Hold → Buy | — | $2.88 | $3.27 | +13.5% | +37.8% | -8.3% | +1.4% | -6.5% | +5.2% |
| Mar 26 | BTIG | Upgrade | Neutral → Buy | — | $2.25 | $2.46 | +9.3% | +28.0% | +37.8% | -8.3% | +1.4% | -6.5% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.39 | $2.41 | +0.8% | +4.2% | -2.0% | -2.0% | -2.5% | +3.4% |
| Mar 1 | Wedbush | Maintains | Outperform → Outperform | — | $1.87 | $1.86 | -0.5% | +19.3% | -4.9% | +2.8% | +9.6% | +4.2% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.24 | $1.25 | +0.8% | +1.6% | +3.2% | -2.3% | +0.0% | +3.9% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.68 | $1.68 | +0.0% | -1.2% | -1.2% | +1.8% | -1.8% | +0.0% |
| May 5 | RBC Capital | Maintains | Outperform → Outperform | — | $1.62 | $1.62 | +0.0% | +3.1% | -3.0% | -0.6% | +0.0% | +0.0% |
| Jan 6 | Jefferies | Downgrade | Buy → Hold | — | $2.03 | $2.00 | -1.5% | -2.0% | +2.5% | +11.3% | -3.5% | +4.6% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.83 | $2.74 | -3.2% | +1.4% | +0.7% | +4.5% | -1.0% | -2.0% |
| Aug 2 | BMO Capital | Downgrade | Outperform → Market Perform | — | $2.49 | $2.37 | -4.8% | -8.0% | +0.9% | +2.6% | +5.1% | +6.0% |
| Aug 2 | BTIG | Downgrade | Buy → Neutral | — | $2.49 | $2.37 | -4.8% | -8.0% | +0.9% | +2.6% | +5.1% | +6.0% |
No insider trades available.
Data updated apr 26, 2026 4:10pm
· Source: massive.com